From GlobeNewswire: 2025-01-02 07:45:00

Clearmind Medicine Inc. announces advancement in its MEAI-based binge behavior regulator program with patent approval from the Macau International Intellectual Property Office. The allowed patent covers the use of primary amine aminoindan compounds, including MEAI, to regulate binge behavior. This strengthens Clearmind’s global IP portfolio, now with 31 granted patents in major jurisdictions. CEO Dr. Adi Zuloff-Shani believes this patent supports their mission to develop transformative treatments for substance addictions related to alcohol and food. Clearmind is a clinical-stage biotech company focused on psychedelic-derived therapeutics for health issues like alcohol use disorder. Shares are listed on Nasdaq and FSE under “CMND” and “CWY0” respectively.



Read more at GlobeNewswire: Clearmind Medicine Granted Patent for Binge Behavior